Seneca Therapeutics, Inc. is pursuing the development of an oncolytic immune-Seneca Valley Virus (SVV) and derivatives as cancer therapeutics, cancer vaccines, and as vaccines for infectious diseases. SVV is an oncolytic virus that eliminate tumor cells in which it can replicate.